Akston's twice-yearly itch shot matches Cytopoint, and targets its monthly-dosing model

AKS-699 matches lokivetmab on far fewer injections

The data came out of a head-to-head canine IL-31 challenge study, presented at the North American Veterinary Dermatology Forum in Indianapolis. Both AKS-699 and lokivetmab produced rapid, marked drops in challenge-induced itch versus control. The difference was the schedule. Lokivetmab is dosed monthly. AKS-699 reached comparable control on three induction doses and one booster at six months.

The mechanism is the reason for the gap. Cytopoint delivers a ready-made monoclonal antibody that the body clears over weeks, which is why it needs re-dosing. AKS-699 instead provokes the dog's own immune system to produce sustained anti-IL-31 antibodies. It is built on Akston's Ambifect Fc-fusion platform, formulated with an adjuvant, and given as a fixed dose rather than weight-based, because the response scales with the animal.

Akston reported the candidate was well tolerated across the study. Injection-site reactions in both arms were mild and resolved within one to three days, with no clinically meaningful adverse findings.

Two limits belong next to the headline. This is preclinical, run in an artificial IL-31 challenge model, not in dogs with naturally occurring atopic dermatitis. And AKS-699 is investigational, with no approval and no filed pivotal trial. The company says its next step is moving into client-owned dogs with real disease.

Why fewer injections threatens a recurring-revenue franchise

Dermatology is one of the most durable franchises in animal health, and one of Zoetis's largest. The company built it on two products: Apoquel, the daily oral JAK inhibitor approved in 2013, and Cytopoint, the monthly antibody injection launched in 2017. Together they have treated tens of millions of dogs and anchor a key-dermatology line Zoetis still reports as a top growth driver.

That franchise runs on repeat visits, and the strain is already visible. In its 2025 results, Zoetis flagged softening Cytopoint sales tied to lower dermatology clinic visits, even as Apoquel kept growing. A monthly injection is a monthly reason to come back, and the compliance burden Akston is attacking is the same burden that produces the recurring revenue. Roughly 10 to 15% of dogs carry atopic dermatitis, so the installed base is enormous and chronic.

Now read the value proposition the way a clinic owner does. An extended-interval shot that holds itch for six months changes three things at once: the visit cadence, the per-patient revenue timing, and the compliance math that decides whether a dog stays on therapy at all. Owners who lapse on a monthly regimen because of cost or hassle are the leak in the system. Cut dosing to twice a year and the leak narrows, but so does the visit-driven revenue line that derma franchises are modeled on.

The active-immunization approach also rewrites the cost structure. Fixed dosing removes weight-based SKUs and the inventory complexity that comes with them. Self-produced antibodies sidestep the cost of manufacturing and shipping monoclonal protein for every dose. If those economics hold through real trials, the challenger competes on price as well as convenience, which is the harder combination to defend against.

None of this is a 2026 problem for Zoetis. The runway from a challenge model to a commercial label in veterinary biologics is measured in years, and incumbents have time to respond, including with their own longer-acting formats. But the strategic signal is clear. The next fight in pet derma is about dosing interval, and a well-funded challenger just put a number on the board.

What client-owned dog trials will decide

The gap between this readout and a product comes down to a few specific gates. Watch them in order.

The disease model. Challenge-study itch is induced on demand. Naturally occurring atopic dermatitis flares unpredictably and varies by dog. Comparable control in client-owned animals with real disease is the result that matters, and Akston has said that study is the next step.

Durability and the booster question. The company plans to characterize how long the response lasts and whether an annual booster is enough. Twice-yearly is the headline; once-yearly would be a different conversation entirely.

Manufacturing. Akston points to a new biologics facility in Louisiana to support clinical supply and commercial-scale production. Scale-up is where a lot of veterinary biologics stall, so capacity is a real variable, not a footnote.

The incumbent response. Zoetis is not standing still, and Elanco has pushed into the same itch market with its oral JAK inhibitor Zenrelia. A longer-acting Cytopoint, or aggressive contracting on the existing line, is the obvious counter.

For operators, the decision this informs is not "switch tomorrow." It is whether to assume monthly-injection economics hold for the rest of the decade. This readout is the first concrete reason to assume they might not.